Small logo Subscribe to leading news on impact investing. Learn More
The Brief Originals Dealflow Signals The Impact Alpha Impact Voices Podcasts Agents of Impact Open
What's Next Capital on the Frontier Measure Better Investing in Racial Equity Beyond Trade-offs Impact en las Americas New Revivalists
Local and Inclusive Climate Finance Catalytic Capital Frontier Finance Best Practices Geographies
Slack Agent of Impact Calls Events Contribute
The Archive ImpactSpace The Accelerator Selection Tool Network Map
About Us FAQ Calendar Pricing and Payment Policy Privacy Policy Terms of Service Agreement Contact Us
Locavesting Entrepreneurship Gender Smart Return on Inclusion Good Jobs Creative economy Opportunity Zones Investing in place Housing New Schooled Well Being People on the Move Faith and investing Inclusive Fintech
Clean Energy Farmer Finance Soil Wealth Conservation Finance Financing Fish
Innovative Finance
Personal Finance Impact Management
Africa Asia Europe Latin America Middle East Oceania/Australia China Canada India United Kingdom United States
Subscribe
Features
Series
Themes
Community
Data
Subscribe Log In
More

The Global Health Investment Fund backs eye care device startup Iantech



Half of global blindness is caused by untreated cataracts.

The GHIF, along with the Visionary Venture Fund invested in the surgical eyecare venture to lower the cost and increase the effectiveness of cataract surgery.

The GHIF is a joint fund between the Bill & Melinda Gates Foundation and JPMorgan Chase.

Iantech has developed a cataract surgery device called miLOOP to make surgery “more efficient, less invasive, less dependent on capital-intense [devices], and easier to learn.”

The device has already been commercialized in the U.S.; the investment is focusing on the miLOOP’s global potential.

“Because extremely advanced cataracts are so prevalent among poor populations, we have a promising new technology that will be welcomed by surgeons both in the most advanced Western centers as well as in the developing world,” says David Chang, an Iantech advisory board member.

You might also like...